Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends
Celgene will stop late-stage testing of its investigative therapy mongersen for Crohn’s disease after a data monitoring committee said it would be futile to continue.
You may also be interested in...
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
Documents detailing negotiations over the proposed Bristol/Celgene merger show Bristol’s offer decreased over time, but Celgene may still come out ahead. Effort to find another bidder failed, however.
Emerging Company Profile: Start-up Landos is raising money through a Series B financing to fund Phase II development of its lead oral, gut-restricted compound and described its plans in a video interview at the Biotech Showcase in San Francisco in January.